This might be the consequence of the reduction of EGFR, MIEN1, or Transgelin-2 identified by our proteomic and described to foster tumor development [40–42], and/or the result of enhanced necroptosis (12 deregulated proteins identified by proteomic), S100A11 having recently been identified as a necroptosis-related gene signature in HCC [43]. The gene discussed is S100A11; the disease is neoplasm.